A critical analysis of the review on antimicrobial resistance report and the infectious disease financing facility

Globalization and Health

Volumn 12, Issue 1, 2016, Pages

  Brogan, David M ^a,b   Mossialos, Elias ^a  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

Antibiotic development; International Disease Financing Facility; Review on Antimicrobial Resistance

Indexed keywords

ANTIBIOTIC RESISTANCE; COOPERATION; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; FEASIBILITY STUDY; FUNDING; HEALTH CARE FACILITY; INVESTMENT; NOTE; PRIORITY JOURNAL; PROFIT; PUBLIC HEALTH; SOCIAL PARTICIPATION; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; DRUG EFFECTS; FINANCIAL MANAGEMENT; HUMAN; INTERNATIONAL COOPERATION; PROCEDURES;

ANTIINFECTIVE AGENT;

ANTI-BACTERIAL AGENTS; CAPITAL FINANCING; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; DRUG RESISTANCE, MICROBIAL; HUMANS; INTERNATIONAL COOPERATION; PUBLIC HEALTH;

EID: 84962532585     PISSN: None     EISSN: 17448603     Source Type: Journal    
DOI: 10.1186/s12992-016-0147-y     Document Type: Note

References (21)

1. O'Neill J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Rev Antimicrob Resist. 2014. http://amr-review.org/Publications.
2. Mossialos E, Morel CM, Edwards S, Berenson J, Gemmill-Toyama M, Brogan D. Policies and Incentives for Promoting Innovation in Antibiotic Research. Copenhagen: World Health Organization and Swedish Ministry of Social affairs and Health; 2010.
3. Matthiessen L. Infectious Disease Financing Facility (IDFF). Horizon 2020 SC1 Advisory Group for the "Health, demographic change and well-being". Brussels: European Commission; 2015.
4. O'Neill J. Securing New Drugs for Future Generations: The Pipeline of Antibiotics. London: Wellcome Trust; 2015.
5. Renwick M, Brogan D, Mossialos E. A Critical Assessment of Incentive Strategies for Development of Novel Antibiotics. J Antibiot. 2015; doi: 10.1038/ja.2015.98
6. Morel CM, Mossialos E. Stoking the antibiotic pipeline. BMJ. 2010;18(340):c2115.
7. Sharma P, Towse A. New drugs to tackle antimicrobial resistance: analysis of EU policy options. London: Office of Health Economics; 2010.
8. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov. 2009;8(12):959-68.
9. Cecchini M, Langer J, Slawomirski L. Antimicrobial Resistance in G7 Countries and Beyond: Economic Issues, Policies and Options for Action. Paris: Organization for Economic Co-operation and Development; 2015.
10. Harper M. The Truly Staggering Cost of Inventing New Drugs. Forbes, 2012. Available from: www.forbes.com/sites/matthewherper/2012/02/10/the-truly-staggering-cost-of-inventing-new-drugs/2715e4857a0b70d756604477. Accessed on October 7, 2015.
11. DiMasi J, editor. Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs. Boston: R&D Cost Study Briefing; 2014.
12. Avorn J. The $2.6 Billion Pill-Methodologic and Policy Considerations. N Engl J Med. 2015;372(20):1877-9.
13. Monnet DL. Antibiotic development and the changing role of the pharmaceutical industry. Int J Risk Safety Med. 2005;17(3):133-45.
14. Innovative Medicines Initiative. The IMI funding model Innovative Medicines Initiative. Brussels: European Commission; 2015. Available from: http://www.imi.europa.eu/content/imi-funding-model. Accessed on October 7, 2015.
15. Elmer C, Grossenbacher T, Gruhnwald S, Schafer M. The People Pay, Corporations Cash In: Problems Plague EU Medical Research Initiative. Der Spiegel. 2015;1:2015.
16. Garattini S, Bertele V, Bertolini G. A failed attempt at collaboration. BMJ. 2013;347:f5354. doi: 10.1136/bmj.f5354.
17. Brogan D, Mossialos E. Applying the concepts of financial options to stimulate vaccine development. Nat Rev Drug Discov. 2006;5(8):641-7.
18. Brogan DM, Mossialos E. Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model. Glob Health. 2013;9(1):58.
19. Russell PK. Project BioShield: what it is, why it is needed, and its accomplishments so far. Clin Infect Dis. 2007;45 Suppl 1:S68-72.
20. World Health Organization. Publicly Financed Global Consortium for R&D to Fight Antibiotic Resistance. Geneva: World Health Organization; 2014.
21. Joint Programming Initiative on Antimicrobial Resistance. Strategic Research Agenda. The Hague: Joint Programming Initiative on Antimicrobial Resistance; 2013.